SCHEDULE 13G/A: North Run Capital Group Discloses 9.3% Stake in TELA Bio, Inc.

A group of investment entities and individuals, led by North Run Capital, LP, has filed an amended Schedule 13G disclosing a collective beneficial ownership of 9.3% of TELA Bio, Inc.'s common stock.

Summary

• North Run Capital, LP, North Run Advisors, LLC, North Run Due North Partners, LP, North Run GP, LP, Todd B. Hammer, Thomas B. Ellis, and Michael Bosco (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 3,682,489 shares of TELA Bio, Inc. Common Stock.
• This ownership represents approximately 9.3% of the outstanding shares of Common Stock.
• The percentage is based on 39,554,771 shares of Common Stock outstanding as of March 31, 2025, as reported in TELA Bio, Inc.'s Quarterly Report on Form 10-Q filed on May 8, 2025.
• The Reporting Persons have shared voting power and shared dispositive power over all 3,682,489 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The disclosure of a significant 9.3% stake by an investment group can be viewed as a moderately positive signal of investor confidence, although the filing itself is neutral in tone and purpose (passive investment).

Positives

• A significant institutional investor group, North Run Capital and its affiliates, holds a substantial 9.3% stake in TELA Bio, Inc., indicating a notable level of investment and potential confidence in the company.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an investment group in a publicly traded company. It does not provide specific industry trends or competitive analysis but indicates institutional interest in the medical technology or biotechnology sector, where TELA Bio, Inc. likely operates.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.3% stake by an institutional group may influence investor perception and potentially the stock price, signaling confidence or interest from a notable investor.

Key Dates

Keywords

TELA Bio Inc., North Run Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management, Shareholding